Ascendis Pharma A/S (NASDAQ: ASND) stock made a positive start this year and generated over 28.1% in this year to date (as of March 29th, 2018; Source: Yahoo finance). The group’s TransCon Growth Hormone program continue to advance in Phase 3. They finished enrollment in their pivotal heiGHt trial, and started two supporting Phase 3 trials. The group also continue the development of their patient-friendly auto-injector, which would be ready at norms [ph]. Moreover, they published their Phase 2 results and other data to build awareness of the potential best-in-class program.
TransCon GH has moved to a potential first-to-market position changes and is well-positioned in this market, while the group expects a top line result from their heiGHt trial in the first quarter of 2019. The group started their Phase 1 trial last year and reported positive interim data from both the single and multi-dose cohorts. Both serum and urinary calcium should be normalized by restoring PTH to physiological levels for 24 hours a day. The group intends to finish this trial in the second quarter, and would report data at medical conferences and business update. They forecasts to start Phase 3 in the first quarter of 2019 pending regulatory discussion later this year.
Their TransCon platform technology shows a high level of confidence that their TransCon CNP has the potential to realize its target product profile. The group forecasts to report the clinical data in the third quarter this year supporting their goal to offer patients with FGFR-related diseases and effective treatment without cardiovascular risk.
“The group is aiming to show the data across all three of their clinical programs in the next twelve months, including full data from our ongoing phase 1 trial of TransCon PTH, top-line data from their planned TransCon CNP phase 1 trial, and top-line data from their phase 3 heiGHt Trial for TransCon Growth Hormone. The value of their TransCon technology platform is rising as they move into multiple clinical programs, while the group intends to continue to see the broad applicability of their technology.